Clinical Trials
17
0 active
Approvals
5
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Completed
15
88.2%
Recruiting
1
5.9%
Withdrawn
1
5.9%
- The FDA approved a nonprescription fixed-dose pill combining 325 mg acetaminophen (Tylenol) and 110 mg naproxen sodium for up to 12 hours of pain relief. - The combination pill is indicated for adults and children aged 12 and older for headaches, back pain, muscle aches, toothaches, menstrual cramps, and minor arthritis pain. - The approval aligns with "The Great Healthcare Plan," a federal initiative to expand over-the-counter availability of verified safe pharmaceutical drugs. - Kenvue, the maker of Tylenol, is in the process of being acquired by Kimberly-Clark in a deal valued at more than $40 billion, expected to close this year.
- Kimberly-Clark has agreed to acquire Tylenol maker Kenvue for approximately $48.7 billion in a cash and stock deal that will create a major consumer health company. - The combined entity will generate about $32 billion in annual revenue, uniting iconic brands including Tylenol, Neutrogena, Listerine, and Band-Aid with Kleenex and Huggies. - Kenvue shares surged 18% in premarket trading following the announcement, while the company has faced recent challenges including disappointing earnings since its 2023 spinoff from Johnson & Johnson. - The deal is expected to close in the second half of next year, with Kimberly-Clark shareholders owning 54% of the new combined company.
